Inhibitor timidilatne sintaze
Inhibitori timidilatne sintaze su hemijski agensi koji inhibiraju enzim timidilatna sintaza, te mogu da nađu primenu u antikancernoj hemoterapiji.[1] Pet agenasa je bilo u kliničkim israživanjima 2002: raltitreksed, pemetreksed, nolatreksed, ZD9331, i GS7904L.[2]
Primeri lekova ove klase su:
- Raltitreksed, koristi se za kolorektalni kancer od 1998
- Fluorouracil, koristi se za kolorektalni kancer[3]
- BGC 945[4]
- OSI-7904L[5]
- ↑ Jackman, A.L.; Calvert, A.H. (1995). „Folate-based thymidylate synthase inhibitors as anticancer drugs”. Annals of Oncology 6 (9): 871–881.
- ↑ „Thymidylate synthase inhibitors as anticancer agents: from bench to bedside”. Pristupljeno 2009-01-28.
- ↑ Papamichael, D. (1999). „The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status”. Oncologist 4 (6): 478–87. PMID 10631692.[mrtav link]
- ↑ Gibbs, David D., et al (2005). „BGC 945, a novel tumor-selective thymidylate synthase inhibitor targeted to α-folate receptor-overexpressing tumors”. Cancer Research 65 (24): 11721–11728. DOI:10.1158/0008-5472.CAN-05-2034.
- ↑ Ricart AD, Berlin JD, Papadopoulos KP, et al. (December 2008). „Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors”. Clin. Cancer Res. 14 (23): 7947–55. DOI:10.1158/1078-0432.CCR-08-0864. PMID 19047127.